Ritwika Mallik

Dr. Ritwika Mallik


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Journal of Diabetes Science and Technology
Verified
Journal Article
Closed access
PDF file
RMRitwika Mallik
Ritwika Mallik
MPMayank Patel
Mayank Patel
BABen Atkinson
Ben Atkinson
PKPartha Kar
Partha Kar
Background: It is estimated that 16 to 25% of patients in hospital have diabetes and 1 in 25 inpatients with Type 1 Diabetes develop diabetic ketoacidosis (DKA). It is vital that non-specialist doctors recognize and appropriately manage diabetes emergencies. Simulation training is increasingly being used in healthcare and virtual reality (VR) based educational resources is transforming medical education. This study aimed to evaluate the use of virtual reality to help non-specialist clinicians manage clinical scenarios related to diabetes. Methods: This pilot project, titled ‘DEVICE’ (Diabetes Emergencies: Virtual Interactive Clinical Education) was developed in collaboration with Oxford Medical Simulation. Fully interactive immersive VR scenarios were created to stimulate real life diabetes emergencies. Users then received personalized feedback and performance metrics. Feedback surveys were provided before and after the participation in the VR scenario. Kirkpatrick’s training evaluation model was used. Results: Thirty-nine participants from 2 hospitals in UK provided feedback up to 3 months after attending the VR education sessions. Overall feedback was extremely positive, and participants found this immersive teaching experience very helpful. After use of virtual reality scenarios, the mean trainee confidence in managing DKA (on an 8-point Likert scale) increased from 3.92 (3.38-4.47) 95% CI to 5.41 (4.79-6.03) 95% CI (statistically significant). The VR study demonstrates Kirkpatrick level 3 in the follow up survey. Conclusion: VR based training scenarios in this pilot project increased confidence in managing diabetes emergencies and demonstrated positive changes in their behavior. VR education is a safe, useful and a well-liked training tool for diabetes emergencies.

30 July 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
OMOwen Marples
Owen Marples
LRLaura Resca
Laura Resca
JPJulija Plavska
Julija Plavska
SHSamina Hassan
Samina Hassan
VMVibhuti Mistry
Vibhuti Mistry
ABAdrian Brown
Adrian Brown
(1) Background: Formula low energy diets (LED) are effective at inducing weight loss and type 2 diabetes (T2DM) remission. However, the effect of LED programmes in ethnic minority groups in the UK is unknown. (2) Methods: A service-evaluation was undertaken of a group-based LED, total diet replacement (TDR) programme in London, UK. The programme included: a 12-week TDR phase, 9-week food reintroduction and a 31-week weight maintenance phase and was delivered by a diabetes multi-disciplinary team. (3) Results: Between November 2018 and March 2020, 216 individuals were referred, 37 commenced the programme, with 29 completing (78%). The majority were of Black British (20%) ethnicity with a mean (SD) age of 50.4 (10.5) years, a body mass index of 34.4 (4.4) kg/m2 and a T2DM duration of 4.2 (3.6) years. At 12 months, 65.7% achieved T2DM remission, with a mean bodyweight loss of 11.6 (8.9) kg. Completers lost 15.8 (5.3) kg, with 31.4% of participants achieving ≥15 kg weight loss. Quality of life measures showed significant improvements. (4) Conclusions: This service evaluation shows for the first time in the UK that a group-based formula LED programme can be effective in achieving T2DM remission and weight loss in an ethnical diverse population.

1 February 2023 in Current Diabetes Reviews
Verified
Journal Article
Closed access
PDF file
MHM.S. Bobby Huda
M.S. Bobby Huda
RMRitwika Mallik
Ritwika Mallik
Gestational diabetes mellitus (GDM) is associated with fetal and maternal complications, and the prevalence has been increasing over the past decades. Hence, it is imperative to effectively screen, manage and monitor patients with GDM but there continues to be a lack of consensus on optimal screening for GDM internationally. In this review, we discuss the current screening methods for GDM, some of which are controversial and vary across several different healthcare systems. We also discuss the changes adapted to these guidelines during the COVID-19 pandemic and review novel approaches to the screening of GDM.

15 February 2024 in Gastrointestinal Disorders
Verified
Journal Article
Open access
PDF file
BNBenjamin Charles Norton
Benjamin Charles Norton
APApostolis Papaefthymiou
Apostolis Papaefthymiou
ATAndrea Telese
Andrea Telese
RMRitwika Mallik
Ritwika Mallik
AMAlberto Murino
Alberto Murino
RHRehan Jamil Haidry
Rehan Jamil Haidry
Type 2 diabetes (T2D) is one of the most significant and fast-growing health challenges of the 21st century. Despite the variety of available glucose-lowering agents, many patients do not attain or maintain adequate glycaemic control. Bariatric surgery demonstrates a profound anti-diabetic effect, which is almost immediate and weight-loss independent. The significant improvement in diabetes after bariatric surgery together with the endoscopic accessibility of the duodenum has led to the development of new metabolic endoscopic procedures that capitalise on the importance of the proximal small bowel in glycaemic control. Clinical trials have shown a clear efficacy signal, and now, several devices are undergoing evaluation as primary T2D treatments. Establishing where these procedures fit into the treatment algorithms for T2D and how they can be combined with modern pharmacotherapies is needed in a rapidly changing landscape. Ultimately, through metabolic endoscopy, gastroenterologists are on the cusp of providing safe and effective treatments for the multidisciplinary management of T2D.

13 September 2025 in Clinical Medicine
Verified
Journal Article
Open access
DMDorcas Mukuba
Dorcas Mukuba
RMRitwika Mallik
Ritwika Mallik
TCTahseen A. Chowdhury
Tahseen A. Chowdhury
Transplantation is both a cause of, and a therapy for diabetes. Solid organ transplantation requires immunosuppressive regimens which frequently cause temporary or permanent hyperglycaemia which can influence the outcome of allograft function and also increase cardiovascular mortality and morbidity. Post-transplant diabetes should be actively screened for and managed in the early post-transplant period and should also be screened for long term in all solid organ transplant recipients. Transplantation of whole pancreas or pancreatic islets is a long-established therapy for people with Type 1 diabetes and severe hypoglycaemia unawareness. Both procedures may be done in association with other solid organ transplants, most commonly with kidney transplantation. They can induce insulin independence and improve allograft survival. Recently, stem cell derived therapy for Type 1 diabetes has been shown to be possible in humans and is likely to become an important therapy for people living with T1D.

26 February 2026 in Primary Care Diabetes
Verified
Journal Article
Open access
RMRitwika Mallik
Ritwika Mallik
OMOwen Marples
Owen Marples
SVShanti Vijayaraghavan
Shanti Vijayaraghavan
CGChristopher Garrett
Christopher Garrett
TCTahseen A. Chowdhury
Tahseen A. Chowdhury
MHMohammed Sb Huda
Mohammed Sb Huda
The North-East London Type 1 Diabetes Transformation (NATALIE) Project aimed to accurately provide data on place of care for people with type 1 diabetes (T1D) and assess the impact of interventions to engage people with T1D not accessing specialist care or those assigned to a high-risk register. Systematic searches were carried out to identify dual coding/no coding for type of diabetes and were followed by practice level case note review by a healthcare professional (HCP). The Clinical Effectiveness Group (CEG), which is a local primary care-led clinical academic group, was commissioned to aid with data searches. In City & Hackney, following the audit, the impact of pilot interventions was evaluated. These included a primary care toolkit, to improve engagement and of focused clinical care for those assigned to a high-risk register (HbA1c >75 mmol/mol) were analysed. One hundred and fifty general practitioner (GP) practices engaged and 2499 patient records were reviewed. The proportion of people with T1D receiving care in primary care alone varied from 12.9 % to 37.7 % with a mean of 30 %. Following interventions including secondary care referral, referring for Freestyle Libre monitoring or structured education, the number of people with T1D under primary care alone reduced from 36 % to 24 %. The 85/133 people with T1D on the high-risk register who engaged with focused clinical intervention decreased their HbA1c from 93 mmol/mol to 83 mmol/mol. In an area of high socioeconomic deprivation, the NATALIE project showed that an average of 30 % of people with type 1 diabetes are under primary care alone, and simple interventions improved this by up to 10 %. Furthermore, focused clinical contacts with high-risk people with T1D can reduce HbA1c by 10 mmol/mol.